* If you want to update the article please login/register
Purpose This research investigates whether race, socioeconomic status, insurance type, oncological center type, and prior cancer treatment are all related to the recommendation and acceptance of hormonal therapy in patients with estrogen receptor-positive Ductal carcinoma in situ. Methods This single-center retrospective review included 111 patients with DCIS between 2020 and 2021. Endocrine therapy was administered to 79. 3% of women. Conclusion The authors of this article show that patients'u2019 demographics and providers were not associated with adjuvant hormonal therapy initiation in DCIS. Both the lack of provider recommendation and patient opposition of these drugs led to the cessation of endocrine therapy in DCIS patients, according to our findings. The wide variability in hormonal therapy among ER-positive DCIS patients indicates a need for improved provider-patient collaboration to ensure a joint decision-making process.
Source link: https://doi.org/10.1007/s10549-022-06735-9
A p53 null phenotype has only been discussed in the genitourinary pathology literature, not as a diagnostic biomarker for urothelial carcinoma in situ. Herein, 25 cases of urothelial carcinoma in situ [diagnoses on hematoxylin and eosin stained sections] with null pattern p53 staining were obtained from 22 different patients, with the majority displaying large cell morphology and large cell pleomorphic pattern morphology. In some cases, urothelial CIS is still an H&E diagnosis, but a p53 immunostain may be helpful in a subset of unusual situations. A good response by the p53 null phenotype as a u201cbiologically beneficial result, like stout and diffuse staining with p53, is vital, and may warrant a formal consensus statement for recommended p53 data.
Source link: https://doi.org/10.1038/s41379-022-01062-2
In young women, Ductal carcinoma in situ is rare and understudied. In a modern cohort of women aged u2264-40 years with DCIS, the aim of this report is to report clinicopathologic, diagnosis, and oncologic findings. Patients and Methods Patients with DCIS were enrolled from 2006 to 2016, the Young Women's Breast Cancer Study, a multisite prospective cohort of women diagnosed with stage 0u2013IV breast cancer diagnosed with age u2264-40 years, enrolled from 2006 to 2016. Among the 98 patients included, the median age of diagnosis was 38 years; 36 patients were symptomatic on presentation. Patients were only being treated with tamoxifen therapy one year postdiagnosis. Conclusions A large number of young women with DCIS underwent mastectomy with or without contralateral prophylactic mastectomy. This highlights the importance of careful investigation into treatment choices for young women with DCIS.
Source link: https://doi.org/10.1245/s10434-022-12361-y
* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions